Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1540658X251369691 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutting-edge strategies for delivering drugs to the brain based on nanocarriers.
Drug Dev Ind Pharm
September 2025
Department of Pharmaceutical Technology, Maulana Abul Kalam Azad University of Technology, West Bengal, Nadia, PIN-741249, India.
Objective: This review aims to explore advanced nanotechnology-integrated delivery systems designed to facilitate the transport of therapeutic agents across the blood-brain barrier (BBB) for the treatment of central nervous system (CNS) disorders, particularly neurodegenerative diseases.Significance:CNS disorders remain a primary global health concern due to their progressive nature and limited treatment options. Conventional therapies exhibit minimal efficacy, primarily due to the restrictive nature of the BBB, which impedes drug access to brain tissue.
View Article and Find Full Text PDFNanoengineering of Exosomal Surfaces for Precision Targeting and Payload Delivery at the Molecular Level.
Assay Drug Dev Technol
September 2025
School of Applied Sciences, CT University, Sidhwan Khurd, India.
A SERS-Based Antibody-Aptamer Sandwich Assay for Extracellular Vesicle-Associated Tau Detection Using Gold Nanoparticles.
Adv Sens Res
August 2025
Department of Nanoengineering, Joint School of Nanoscience and Nanoengineering, North Carolina A&T State University, 2907 E Gate City Blvd, Greensboro, NC 27401.
Extracellular vesicles (EVs) have emerged as sources of promising, minimally invasive biomarkers for diagnosing and monitoring diseases like Alzheimer's. Using EVs as a source of biomarkers for neurological diseases is highly relevant because they can carry pathogenic proteins, such as tau and amyloid-β, across the blood-brain barrier and can be easily accessed and collected since they are available in almost all biofluids, including blood, urine, and saliva. Here, a bioanalytical antibody-aptamer sandwich assay detection using surface-enhanced Raman spectroscopy (SERS) is developed to quantify the expression of EV-associated tau.
View Article and Find Full Text PDFAvidity-Based Capture of PD-L1-Expressing Exosomes via Dendrimer-Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response.
Adv Sci (Weinh)
August 2025
Department of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea.
A major challenge in immunotherapy is the inability to reliably predict patient responses due to the lack of robust biomarkers. Programmed cell death-ligand 1 (PD-L1)-expressing exosomes represent a promising biomarker candidate; however, existing detection platforms lack the sensitivity and specificity required for clinical translation. It is hypothesized that an avidity-based capture strategy utilizing dendrimer-mediated multivalent binding will effectively enhance molecular avidity and improve the selective capture of PD-L1-expressing exosomes.
View Article and Find Full Text PDFAdvancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence.
Sci Prog
August 2025
RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras-al-Khaimah, United Arab Emirates.
Breast cancer recurrence remains a major cause of mortality, with up to 30% of early-stage patients relapsing as incurable metastatic disease. Conventional surveillance with imaging and serum markers (CA15-3, CEA) lacks the sensitivity and specificity to detect minimal residual disease. This narrative review examines non-invasive biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and exosomes and the technologies enhancing their performance.
View Article and Find Full Text PDF